Afatinib in advanced NSCLC: a profile of its use.
Afatinib in advanced NSCLC: a profile of its use.
复制标题
DOI：
10.1007/s40267-018-0482-6
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Keating GM
中科院分区：
文献类型：
--
作者：
Deeks ED;Keating GM
阿法替尼 [Giotrif®（欧盟）； Gilotrif®（美国）]是一种口服、不可逆的酪氨酸激酶 ErbB 家族抑制剂，为具有激活表皮生长因子受体（EGFR）突变（即 EGFRactMUT+）的晚期非小细胞肺癌（NSCLC）提供重要的一线治疗选择，并为一线铂类化疗后进展的鳞状 NSCLC 提供额外的治疗选择。相对于一线治疗 EGFRactMUT+ 晚期肺腺癌的吉非替尼，阿法替尼延长了无进展生存期 (PFS) 和治疗失败时间 (TTF)，但没有延长总生存期 (OS)。在此情况下，与基于顺铂的化疗相比，阿法替尼还延长了 PFS，但没有延长 OS；然而，在外显子 19 缺失的患者亚组中，阿法替尼与化疗相比改善了 OS。作为晚期鳞状 NSCLC 的二线治疗，与厄洛替尼相比，阿法替尼延长了 PFS 和 OS，无论 EGFR 突变状态如何。阿法替尼具有可预测且可管理的耐受性。
Afatinib [Giotrif® (EU); Gilotrif® (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations (i.e. EGFRactMUT+), and an additional treatment option for squamous NSCLC that has progressed following first-line platinum-based chemotherapy. Relative to gefitinib in the first-line treatment of EGFRactMUT+ advanced lung adenocarcinoma, afatinib prolonged progression-free survival (PFS) and time to treatment failure (TTF), but not overall survival (OS). Afatinib also prolonged PFS, but not OS, versus cisplatin-based chemotherapy in this setting; however, afatinib improved OS versus chemotherapy in the subgroup of patients with deletions in exon 19. As a second-line treatment for advanced squamous NSCLC, afatinib prolonged PFS and OS compared with erlotinib, regardless of EGFR mutation status. Afatinib had a predictable and manageable tolerability profile.